title: Reply to Dimitrov et al.: VelociSuite technologies are a foundation for rapid therapeutic antibody development.
authors: Regeneron Pharmaceuticals, Inc., Tarrytown, NY 10591 christos.kyratsous@regeneron.com.
authors: Christos A
authors: CA
authors: Kyratsous
authors: Regeneron Pharmaceuticals, Inc., Tarrytown, NY 10591.
authors: William
authors: W
authors: Olson
authors: Regeneron Pharmaceuticals, Inc., Tarrytown, NY 10591.
authors: Neil
authors: N
authors: Stahl
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D057134:Antibodies, Neutralizing / Q000627:therapeutic use*; D018352:Coronavirus Infections / Q000628:therapy*; D006801:Humans; D065207:Middle East Respiratory Syndrome Coronavirus / Q000472:pathogenicity*; D064370:Spike Glycoprotein, Coronavirus / Q000276:immunology*
chemical_list: D000911:Antibodies, Monoclonal; D057134:Antibodies, Neutralizing; D064370:Spike Glycoprotein, Coronavirus